Citations

Clear

941 citation(s) found for "Tefferi, A".

Ruxolitinib as first‐line treatment in secondary hemophagocytic lymphohistiocytosis: A second experience
Zandvakili, Inuk , Conboy, Caitlin B. , Ayed, Ayed O. , Tefferi, Ayalew , Cathcart-Rake, Elizabeth J., Tefferi, Ayalew , Ayed, Ayed , Cathcart-Rake, Elizabeth , Conboy, Caitlin B

Mayo Clinic

American Journal of Hematology | February 8, 2018 | Volume: 93 | Issue: 5 | Pages: No page available

10.1002/ajh.25063 | PMID 29417621 Get It

Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis
Tefferi, Ayalew , Partain, Daniel K. , Palmer, Jeanne , Slack, James L., Litzow, Mark, Patnaik, Mrinal M. , Palmer, Jeanne M., Litzow, Mark L, Patnaik, Mrinal , Partain, Daniel K , Roy, Vivek , Hogan, William J. , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | February 1, 2018 | Volume: 93 | Issue: 5 | Pages: 649-654

10.1002/ajh.25053 | PMID 29388258 Get It

AbstractThe prognostic importance of genetic information in primary myelofibrosis (PMF) was recently highlighted in a study of over 1000 cytogenetically‐annotated patients; 5‐year survival rates were 8% for very high risk (VHR), 27% “unfavorable” and 45% “favorable” karyotype. The current study addresses the practice‐relevant question of whether or not allogeneic hematopoietic stem cell transplant (HCT) can overcome the detrimental survival effect of VHR or unfavorable karyotype. The study included 67 patients with PMF or secondary MF who received HCT at the Mayo Clinic and in whom pretransplant cytogenetic information was available. Dynamic international prognostic scoring system (DIPSS) risk distribution was 13% high, 66% intermediate‐2 and 21% intermediate‐1. Cytogenetic risk distribution was 11% VHR, 34% unfavorable and 55% favorable. At median post‐HCT follow‐up of 60 months for living patients (range 34‐170), 28 (42%) deaths were recorded. Five‐year survival was 62% and was not affected by VHR or unfavorable karyotype (P = .68). The salutary effect of HCT in patients with VHR or unfavorable karyotype was also apparent during analysis of a combined dataset that included a nontransplant cohort of 383 patients with PMF; multivariable analysis of the combined dataset (n = 450) resulted in HRs (95% CI) of 2.4 (1.6‐3.6) for absence of transplant, 3.3 (2.2‐4.8) for VHR karyotype, 1.6 (1.2‐2.1) for unfavorable karyotype, 2.9 (2.0‐4.2) for DIPSS high and 1.7 (1.4‐2.2) for DIPSS intermediate‐2. These observations were further confirmed by analysis of more stringently matched case‐control subset cohorts and provide the evidence for the therapeutic preference of HCT in cytogenetically high risk patients with MF.
FGFR1rearranged hematological neoplasms – molecularly defined and clinically heterogeneous
Patnaik, Mrinal M. , Tefferi, Ayalew , Ketterling, Rhett P.

Mayo Clinic

Leukemia & Lymphoma | January 31, 2018 | Volume: 59 | Issue: 7 | Pages: 1520-1522

10.1080/10428194.2018.1429607 | PMID 29384399 Get It

A retrospective survey of exposure history to chemotherapy or radiotherapy in 940 consecutive patients with primary myelofibrosis
Nicolosi, Maura , Mudireddy, Mythri , Patnaik, Mrinal M. , Gangat, Naseema , Pardanani, Animesh , Tefferi, Ayalew

Mayo Clinic

American Journal of Hematology | January 12, 2018 | Volume: 93 | Issue: 4 | Pages: No page available

10.1002/ajh.25037 | PMID 29327469 Get It

JAK2 exon 12 mutated polycythemia vera: Mayo‐Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease
Tefferi, Ayalew , Lavu, Sravanthi , Mudireddy, Mythri , Finke, Christy M. , Gangat, Naseema , Pardanani, Animesh , Hanson, Curtis A. , Mannarelli, Carmela, Lasho, Terra L. , Gangat, Naseema , Vannucchi, Alessandro M , Guglielmelli, Paola , Vannucchi, Alessandro M.

Mayo Clinic

American Journal of Hematology | December 24, 2017 | Volume: 93 | Issue: 4 | Pages: No page available

10.1002/ajh.25017 | PMID 29274140 Get It

Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis
Tefferi, Ayalew , Shah, Sahrish, Mudireddy, Mythri , Barraco, Daniela , Hanson, Curtis A. , Elliott, Michelle A. , Patnaik, Mrinal S., Pardanani, Animesh , Gangat, Naseema , Lasho, Terra L. , Barraco, Daniela , Gangat, Naseema , Ketterling, Rhett P. , Patnaik, Mrinal S.

Mayo Clinic

British Journal of Haematology | December 19, 2017 | Volume: 183 | Issue: 5 | Pages: 835-838

10.1111/bjh.15061 | PMID 29265333 Get It

Splanchnic vein thrombosis in patients with myeloproliferative neoplasms: The Mayo clinic experience with 84 consecutive cases
Lavu, Sravanthi , Mudireddy, Mythri , Yogarajah, Meera , Gangat, Naseema , Pardanani, Animesh , Hanson, Curtis A. , Ashrani, Aneel A. , Kamath, Patrick S. , Tefferi, Ayalew , Szuber, Natasha , Mudireddy, Mythri , Gangat, Naseema , Tefferi, Ayalew , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | December 1, 2017 | Volume: 93 | Issue: 3 | Pages: No page available

10.1002/ajh.24993 | PMID 29194707 Get It

Polycythemia vera and essential thrombocythemia: algorithmic approach
Tefferi, Ayalew , Vannucchi, Alessandro M. , Guglielmelli, Paola

Mayo Clinic

Current Opinion in Hematology | November 30, 2017 | Volume: 25 | Issue: 2 | Pages: 112-119

10.1097/moh.0000000000000402 | PMID 29194068 Get It

Purpose of review To describe an algorithm-based approach, whenever available, to the diagnosis, the risk stratification criteria informing therapy and the current management of polycythemia vera and essential thrombocythemia. Recent findings Description of recurrent genetic abnormalities in driver genes, including Janus Kinase 2 (JAK2), myeloproliferative leukemia and calreticulin, a better appreciation of the key diagnostic role of bone marrow features, results of large epidemiologic studies and a few but landmark controlled clinical trials produced in the last decade, all resulted in a reappraisal of the approach to polycythemia vera and essential thrombocythemia. Summary The revised 2017 WHO classification of polycythemia vera and essential thrombocythemia allows early diagnosis and accurate distinction from other chronic myeloproliferative neoplasms, particulary prefibrotic myelofibrosis. The prognostic value of selected mutations is being appreciated and JAK2V617F mutation is currently incorporated as risk variable in prognostic system for essential thrombocythemia. Risk-adjusted stratification is used to select therapeutic approaches that include target agents. However, there is not yet a curative approach to these hematologic neoplasms, and although their management has much improved in the last decades, the associated morbidity and mortality remains significant and may be worsened by toxicities of therapeutic agents. Therefore, several clinically relevant endpoints remain unmet.
Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision‐making in otherwise low or intermediate‐1 risk patients with myelofibrosis
Tefferi, Ayalew , Hanson, Curtis A. , Gangat, Naseema , Pardanani, Animesh , Lasho, Terra L. , Gangat, Naseema , Ketterling, Rhett P.

Mayo Clinic

British Journal of Haematology | November 24, 2017 | Volume: 183 | Issue: 4 | Pages: 678-681

10.1111/bjh.15010 | PMID 29171022 Get It

Driver mutations and prognosis in primary myelofibrosis: Mayo‐Careggi MPN alliance study of 1,095 patients
Tefferi, Ayalew , Nicolosi, Maura , Mudireddy, Mythri , Finke, Christy M. , Hanson, Curtis A. , Pardanani, Animesh , Gangat, Naseema , Mannarelli, Carmela, Fanelli, Tiziana , Szuber, Natasha , Lasho, Terra L. , Gangat, Naseema , Vannucchi, Alessandro M , Ketterling, Rhett P. , Guglielmelli, Paola , Vannucchi, Alessandro M.

Mayo Clinic

American Journal of Hematology | November 22, 2017 | Volume: 93 | Issue: 3 | Pages: 348-355

10.1002/ajh.24978 | PMID 29164670 Get It

Abstract The 2013 discovery of calreticulin ( CALR ) mutations in myeloproliferative neoplasms was attended by their association with longer survival in primary myelofibrosis (PMF). Subsequent studies have suggested prognostic distinction between type 1/like and type 2/like CALR mutations and detrimental effect from triple‐negative mutational status. Among 709 Mayo Clinic patients with PMF, 467 (66%) harbored JAK2 , 112 (16%) CALR type 1/like, 24 (3.4%) CALR type 2/like, 38 (5.4%) MPL mutations and 68 (10%) were triple‐negative. Survival was longer with type 1/like CALR , compared to JAK2 (HR 2.6, 95% CI 1.9‐3.5), type 2/like CALR (HR 2.5, 95% CI 1.4‐4.5), MPL (HR 1.8, 95% CI 1.1‐2.9) and triple‐negative mutational status (HR 2.4, 95% CI 1.6‐3.6), but otherwise similar between the non‐type 1/like CALR mutational states ( P = .41). In multivariable analysis, the absence of type 1/like CALR ( P < .001; HR 2, 95% CI 1.4‐2.7), presence of ASXL1 / SRSF2 mutations ( P < .001; HR 1.9, 95% CI 1.5‐2.4) and DIPSS‐plus ( P < .001) were each predictive of inferior survival. Furthermore, among 210 patients with ASXL1 / SRSF2 mutations, survival was significantly longer in the presence vs. absence of type 1/like CALR mutations (median 5.8 vs. 2.9 years; P < .001). Triple‐negative status did not disclose additional prognostic information for overall or leukemia‐free survival. The observations regarding the prognostic distinction between CALR mutation variants were validated in an external cohort of 386 patients from the University of Florence Careggi hospital. We conclude that type 1/like CALR mutations in PMF not only predict superior survival, but also partially amend the detrimental effect of high molecular risk mutations.